What's fueling the biotech engine--2008.
Despite the global economic slowdown, biologics managed single-digit growth in 2008, driven mainly by continued high growth in sales of antibodies and insulins. Novel biologics in development look promising, but crowding, pricing and reimbursement are emerging as longer-term concerns.